Global Monoclonal Antibodies Market

Monoclonal Antibodies Market Size, Share, Growth Analysis, By Source(Murine, Chimeric), By Production Type(In Vivo, and In Vitro), By Application(Oncology, Autoimmune Diseases), By End Use(Hospitals, Specialty Centers) - Industry Forecast 2024-2031

Report ID: SQMIG35H2248 | Region: Global | Published Date: May, 2024
Pages: 211 | Tables: 119 | Figures: 75

To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Monoclonal Antibodies Market size was valued at USD 210 billion in 2022 and is poised to grow from USD 233.1 billion in 2023 to USD 537.19 billion by 2031, growing at a CAGR of 11% in the forecast period (2024-2031).

Monoclonal antibody companies should focus on reducing their time-to-market and fast track their commercialization processes to boost revenue generation. Collaborations and partnerships will be of the essence for companies looking to hasten their product launches and gain a competitive advantage over other market players. Monoclonal antibody market players can also take advantage of supportive government initiatives and grants for medical research related to monoclonal antibodies. 'Abbott Laboratories', 'Johnson & Johnson Services Inc.', 'Amgen Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'AstraZeneca plc', 'Bristol Myers Squibb', 'F. Hoffman-La Roche Ltd.', 'GlaxoSmithKline plc', 'Merck KGaA', 'Novo Nordisk A/S', 'Novartis', 'Bayer AG', 'Daiichi Sankyo Company Limited', 'Biogen Inc.', 'Thermo Fisher Scientific Inc.', 'Viatris Inc.', 'Eli Lilly and Company'

Rising incidence of chronic diseases around the world has boosted the demand for novel treatments and therapeutics, which in turn is driving investments in medical R&D. Monoclonal antibodies play a crucial role in R&D for therapeutics of many chronic diseases and this could bolster market growth going forward.

Biosimilar and Biobetters: Patent expiry of monoclonal antibodies will offer attractive opportunities in the name of biosimilar and biobetter development. Companies can invest in research and development of biosimilars of popular monoclonal antibodies whose patent is going to expire soon and make huge profits in the long run.

North America is estimated to account for a substantial share of the Monoclonal Antibodies Market owing to high investments in medical R&D and the presence of key biotechnology companies. Supportive government initiatives to promote cancer research are also estimated to bolster monoclonal antibody demand in this region. The United States is expected to lead the market growth in this region followed by Canada. of a developed healthcare infrastructure in the countries also bolsters North America’s dominance.

Related Reports

MRI Motion Tracking Systems Market
Buy Now GET FREE SAMPLE
Artificial Intelligence (AI) in Biotechnology Market
Buy Now GET FREE SAMPLE
CT/NG Testing Market
Buy Now GET FREE SAMPLE
High Potency API Contract Manufacturing Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Monoclonal Antibodies Market

Product ID: SQMIG35H2248

$5,300
BUY NOW